ProfileGDS5678 / 1449592_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 64% 64% 64% 61% 64% 62% 62% 67% 70% 64% 64% 66% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0198966
GSM967853U87-EV human glioblastoma xenograft - Control 23.8228664
GSM967854U87-EV human glioblastoma xenograft - Control 33.8503664
GSM967855U87-EV human glioblastoma xenograft - Control 43.8321764
GSM967856U87-EV human glioblastoma xenograft - Control 53.6267661
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8836364
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.802262
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7292862
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0505167
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3489370
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8447364
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8450764
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0069666
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1098968